Hair care

Posts

Global Alopecia Treatment Market

Alopecia Treatment Market Investigation

Alopecia Treatment Market Investigation Highlighting Grow

The Alopecia Treatment Market 2021 – 2027 report covers the important factors driving the growth of the market, untapped opportunities for manufacturers, trends and developments shaping the dynamics of the market and other insights across various key segments.

Alopecia is a condition associated with excessive hair loss or hair damage. Treatment of alopecia plays a key role in modern healthcare, since it aids hair fall prevention and hair regrowth. Unhealthy lifestyle, hormonal imbalance and ageing, are certain the factors causing condition of alopecia.

The global alopecia treatment market size accounted for US$ 7,325.0 million in 2017 and is projected to witness a 4.9% CAGR over the forecast period (2018–2026).

Rising product approvals and launches, along with robust pipelines are expected to drive the global market growth

Rising launches of products along with robust pipelines are expected to propel the global alopecia treatment market over the forecast period. For instance, Fidia Pharma, in November 2018, launched in Italy, Trinov hair growth lotion for growth of hair. Furthermore, Eli Lilly and Company, in September 2018, began clinical trial of phase 2 to assess efficacy and the safety of the drug Baricitinib to treat alopecia areata patients. This study is projected to be over by August 2022.

Increasing initiatives including crowdfunding campaigns along with rising collaborations by market companies is expected to boost the growth of the global alopecia treatment market over the forecast period. For instance, the U.K.-based firm developing restoration therapies cellular hair-HairClone, in 2018, launched its campaign for public crowdfunding, in collaboration with Capital Cell, a company of crowdfunding. Similarly, RepliCel Life Sciences Inc. and Shiseido Company, Limited, in May 2013, declared technology development transfer framework agreement and collaboration for RepliCel’s technology of hair regeneration – RCH-01.

Increasing Alopecia Areata’ prevalence and high focus on development research within North America are expected to boost the growth of the market.

North America region holds the largest share in the global alopecia treatment market, due to rising prevalence of Alopecia Areata and activities of research by market companies. For instance, in 2017, as per the National Alopecia Areata Foundation (NAAF), alopecia areata troubles over 6.8 Mn individuals in the U.S. with 2.1% lifetime risk. Furthermore, the NAAF is focusing on broadening efforts of research through 2 committees, such as the Clinical Research Advisory Council (CRAC) and the Basic Research Advisory Council (BRAC), to develop the Alopecia Areata Treatment Development Program

Rising strategies of acquisition in this region by market companies are key factors expected to drive the growth of the global alopecia treatment market. For instance, Aclaris Therapeutics, Inc., in August 2017, acquired Confluence Life Sciences, Inc. that expanded the immunology and inflammation pipeline of Aclaris with the inclusion of the lead product candidate of Confluence, CDD-450, IL2-inducible T-cell kinase inhibitor, and topical Janus kinase inhibitors.

Furthermore, market players collaborating with regulation authorities along with other governmental organizations is expected to further drive the global North America alopecia treatment market growth during the forecast period. For instance Helomics, Precision Therapeutics Inc., and the National Alopecia Areata Foundation (NAAF), in April, 2019, entered in an agreement for treating people suffering from autoimmune skin disease known as alopecia areata. This agreement was aimed at providing a next-generation patient registry for driving research on novel treatments to people having this disease.

Major Key Players Include In Alopecia Treatment Market: Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., Merck & Co., Inc., Daiichi Sankyo Company, Limited, and Sun Pharmaceutical Industries Ltd.

Main points in Alopecia Treatment Market Report Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Alopecia Treatment Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Alopecia Treatment Industry Impact

Chapter 2 Global Alopecia Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Alopecia Treatment (Volume and Value) by Type
2.3 Global Alopecia Treatment (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Alopecia Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Alopecia Treatment Market Analysis
Chapter 6 East Asia Alopecia Treatment Market Analysis
Chapter 7 Europe Alopecia Treatment Market Analysis
Chapter 8 South Asia Alopecia Treatment Market Analysis
Chapter 9 Southeast Asia Alopecia Treatment Market Analysis
Chapter 10 Middle East Alopecia Treatment Market Analysis
Chapter 11 Africa Alopecia Treatment Market Analysis
Chapter 12 Oceania Alopecia Treatment Market Analysis
Chapter 13 South America Alopecia Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Alopecia Treatment Business
Chapter 15 Global Alopecia Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions

Alopecia Treatment Market Investigation Highlighting Grow

Source

Recent Posts

Global Alopecia Treatment Market

Alopecia Treatment Market Investigation

Alopecia Treatment Market Investigation Highlighting Grow

The Alopecia Treatment Market 2021 – 2027 report covers the important factors driving the growth of the market, untapped opportunities for manufacturers, trends and developments shaping the dynamics of the market and other insights across various key segments.

Alopecia is a condition associated with excessive hair loss or hair damage. Treatment of alopecia plays a key role in modern healthcare, since it aids hair fall prevention and hair regrowth. Unhealthy lifestyle, hormonal imbalance and ageing, are certain the factors causing condition of alopecia.

The global alopecia treatment market size accounted for US$ 7,325.0 million in 2017 and is projected to witness a 4.9% CAGR over the forecast period (2018–2026).

Rising product approvals and launches, along with robust pipelines are expected to drive the global market growth

Rising launches of products along with robust pipelines are expected to propel the global alopecia treatment market over the forecast period. For instance, Fidia Pharma, in November 2018, launched in Italy, Trinov hair growth lotion for growth of hair. Furthermore, Eli Lilly and Company, in September 2018, began clinical trial of phase 2 to assess efficacy and the safety of the drug Baricitinib to treat alopecia areata patients. This study is projected to be over by August 2022.

Increasing initiatives including crowdfunding campaigns along with rising collaborations by market companies is expected to boost the growth of the global alopecia treatment market over the forecast period. For instance, the U.K.-based firm developing restoration therapies cellular hair-HairClone, in 2018, launched its campaign for public crowdfunding, in collaboration with Capital Cell, a company of crowdfunding. Similarly, RepliCel Life Sciences Inc. and Shiseido Company, Limited, in May 2013, declared technology development transfer framework agreement and collaboration for RepliCel’s technology of hair regeneration – RCH-01.

Increasing Alopecia Areata’ prevalence and high focus on development research within North America are expected to boost the growth of the market.

North America region holds the largest share in the global alopecia treatment market, due to rising prevalence of Alopecia Areata and activities of research by market companies. For instance, in 2017, as per the National Alopecia Areata Foundation (NAAF), alopecia areata troubles over 6.8 Mn individuals in the U.S. with 2.1% lifetime risk. Furthermore, the NAAF is focusing on broadening efforts of research through 2 committees, such as the Clinical Research Advisory Council (CRAC) and the Basic Research Advisory Council (BRAC), to develop the Alopecia Areata Treatment Development Program

Rising strategies of acquisition in this region by market companies are key factors expected to drive the growth of the global alopecia treatment market. For instance, Aclaris Therapeutics, Inc., in August 2017, acquired Confluence Life Sciences, Inc. that expanded the immunology and inflammation pipeline of Aclaris with the inclusion of the lead product candidate of Confluence, CDD-450, IL2-inducible T-cell kinase inhibitor, and topical Janus kinase inhibitors.

Furthermore, market players collaborating with regulation authorities along with other governmental organizations is expected to further drive the global North America alopecia treatment market growth during the forecast period. For instance Helomics, Precision Therapeutics Inc., and the National Alopecia Areata Foundation (NAAF), in April, 2019, entered in an agreement for treating people suffering from autoimmune skin disease known as alopecia areata. This agreement was aimed at providing a next-generation patient registry for driving research on novel treatments to people having this disease.

Major Key Players Include In Alopecia Treatment Market: Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., Merck & Co., Inc., Daiichi Sankyo Company, Limited, and Sun Pharmaceutical Industries Ltd.

Main points in Alopecia Treatment Market Report Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Alopecia Treatment Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Alopecia Treatment Industry Impact

Chapter 2 Global Alopecia Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Alopecia Treatment (Volume and Value) by Type
2.3 Global Alopecia Treatment (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Alopecia Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Alopecia Treatment Market Analysis
Chapter 6 East Asia Alopecia Treatment Market Analysis
Chapter 7 Europe Alopecia Treatment Market Analysis
Chapter 8 South Asia Alopecia Treatment Market Analysis
Chapter 9 Southeast Asia Alopecia Treatment Market Analysis
Chapter 10 Middle East Alopecia Treatment Market Analysis
Chapter 11 Africa Alopecia Treatment Market Analysis
Chapter 12 Oceania Alopecia Treatment Market Analysis
Chapter 13 South America Alopecia Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Alopecia Treatment Business
Chapter 15 Global Alopecia Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions

Alopecia Treatment Market Investigation Highlighting Grow

Source

Recent Posts

Hair Transplant Market Growth

Hair Transplant Market Growth

Hair Transplant Market Growth, Trends, Forecast and COVID-19 Impacts (2021 – 2025)

The latest research report on Hair Transplant Market offers a comprehensive examination of the major trends that positively or negatively influence the growth of this industry with respect to the sub-markets, competitive landscape and regional perspective.

Moreover, it focuses on the key growth propellers and lucrative prospects that will enhance the remuneration scope of the market over the forecast period 2021-2025. It also mentions the restraints along with plans to mitigate their impact. In addition, the research literature presents up-to-date information on the Covid-19 pandemic to facilitate stakeholders in effective decision making for the future.

Key highlights from COVID-19 impact analysis:

  • Consequences of Covid-19 on society and economy worldwide
  • Impact of a pandemic on the business development
  • Commotions in the supply and demand chain

Outline of the regional landscape:

  • Geographically, the Hair Transplant market spans North America, Asia Pacific, Europe, South America, Middle East and Africa..
  • The contribution of each region to the growth of the market is meticulously evaluated in the report.
  • Important aspects like pricing, overall sales, returns, and growth rate estimations for each regional contributor are covered in the report.

Other highlights from the Hair Transplant market report:

  • The product terrain of the Hair Transplant market is classified into Surgical and Non-surgical.
  • Verifiable approximations for revenue share and growth rate for each product category are provided.
  • Detailed information related to market share, growth rate, and production patterns of each product type is hosted in the report.
  • The application reach of the Hair Transplant market is classified into Hospitals & Clinics, Hair Transplant Centers, , Geographically, the detailed analysis of production, trade of the following countries is covered in Chapter 4.2, 5, United States, Europe, China, Japan and India.
  • The market share of each application segment together with their respective growth rates over the forecast duration are incorporated in the document.
  • Leading players in the Hair Transplant market are Lisboa Hair Restoration
  • Products manufactured, services offered, production patterns, market valuation, and financials are the prominent players are thoroughly discussed in the report.
  • Complete evaluation of the industry value chain, from the traders and dealers to the distributors and end-users is systematically presented.

Table of Contents:

Chapter 1 is the basis of the entire report. In this chapter, we define the market concept and market scope of Hair Transplant, including product classification, application areas, and the entire report covered area.

Chapter 2 is the core idea of the whole report. In this chapter, we provide a detailed introduction to our research methods and data sources.

Chapter 3 focuses on analyzing the current competitive situation in the Hair Transplant market and provides basic information, market data, product introductions, etc. of leading companies in the industry. At the same time, Chapter 3 includes the highlighted analysis–Strategies for Company to Deal with the Impact of COVID-19.

Chapter 4 provides breakdown data of different types of products, as well as market forecasts. Different application fields have different usage and development prospects of products.

Chapter 5 provides subdivision data of different application fields and market forecasts.

Chapter 6 includes detailed data of major regions of the world, including detailed data of major regions of the world. North America, Asia Pacific, Europe, South America, Middle East and Africa.

Chapters 7-26 focus on the regional market. We have selected the most representative 20 countries from 197 countries in the world and conducted a detailed analysis and overview of the market development of these countries.

Key Points:

Define, describe and forecast the Hair Transplant product market by type, application, end-user and region.

Provide enterprise external environment analysis and PEST analysis.

Provide strategies for the company to deal with the impact of COVID-19.

Provide market dynamic analysis, including market driving factors, market development constraints.

Provide market entry strategy analysis for new players or players who are ready to enter the market, including market segment definition, client analysis, distribution model, product messaging and positioning, and price strategy analysis.

Keep up with international market trends and provide analysis of the impact of the COVID-19 epidemic on major regions of the world.

Analyze the market opportunities of stakeholders and provide market leaders with details of the competitive landscape.

Hair Transplant Market Growth, Trends, Forecast and COVID-19 Impacts (2021 – 2025)

Source

Recent Posts

Global Laser Hair Loss Treatment

Global Laser Hair Loss Treatment

Global Laser Hair Loss Treatment Market Size study, by Product Type, By Application, and Regional Forecasts 2020-2026

Global Laser Hair Loss Treatment Market is expected to fuel growth at a Compound Annual Growth Rate (CAGR) of XX% from 2020 to 2027. The robust growth of the market is subject to the factors associated with such as market drivers, restraints and opportunities, market trends both present and future, and competitive landscape along with the social, political, economic and technological factors.

There are huge opportunities across different application and end-use sectors along with the increasing usage of the product and applications across the major geographies and the potential key countries. Both revenue and volume as per the feasibility is covered under the scope of the study.

Regional Dynamics of the Global Laser Hair Loss Treatment Market

As per the regional analysis, the major four regions covered are Europe, North America, Asia Pacific and the Rest of the World (RoW) (Latin America, Middle East and Africa). The key potential countries have been also covered under these respective major geographies. For an instance, North America is further bifurcated into the U.S., Canada and Mexico. Europe covers France, UK, Germany, Italy and Others.

The countries covered under the scope of Asia Pacific regions are India, China, Japan, South Korea, Taiwan, Australia and Singapore. The rest of the World is further segmented into Central & South America, Middle East and Africa. Market Size and forecast along with the key trend analysis and insights in both qualitative and quantitative terms have been provided in the report from 2020 to 2027.

Competitive Landscape: Market Share Analysis

In this section of the report, the company market share of the key players has been covered extensively in order to under the competition in the market. The strategies adopted by the key players have been mapped, analyzed and then winning strategies and recommendations have been provided in the report. This would help both existing players and new entrants to understand the entire market dynamics and frame their future strategies accordingly.

Key Companies Operating in this Market

NutraStim
Capillus
iRestore
Apira Science
Eclipse Aesthetics
HairMax

Key Highlights of the Laser Hair Loss Treatment Market Report

• Market Segments and other perspectives have been studied across 360-degree perspective
• Both Supply and Demand-side mapping has been done to understand the market scenario
• We have used data triangulation to derive the market numbers
• Our data and analysis have been verified through C-level Executives while conducting primary interviews
• Porter’s Five Forces Analysis, Swot, Analysis, PEST Analysis, Value Chain Analysis and Market Attractiveness would be an added advantage in the report
• Market Size is Provided from 2019 to 2027; whereas CAGR is Provided from 2020 to 2027
• Historical Year: 2019; Base Year: 2020; Forecast Years: 2020 – 2027

Market Segmentation and Scope of the Global Laser Hair Loss Treatment Market

Market by Type
Low-Level Laser
Medium-Level Laser
Others

Market by Application

Males
Females

Market By Geography
North America (U.S., Canada and Mexico)
Europe (France, UK, Germany, Italy and Others)
Asia Pacific (India, China, Japan, South Korea, Taiwan, Australia and Singapore)
Rest of the World (RoW) (Central & South America, Middle East, Africa)

Global Laser Hair Loss Treatment Market Size study, by Product Type, By Application, and Regional Forecasts 2020-2026

Source

Recent Posts

August Is National Hair Loss Awareness Month

August Is National Hair Loss Awareness Month

August Is National Hair Loss Awareness Month

According to the American Hair Loss Association (AHLA), an estimated 50 million men experience some level of hair loss and approximately 35 million women are also affected by thinning hair. To help those who are suffering from this condition, National Hair Loss Awareness Month (NHLAM) delivers attention to detection, prevention, and treatment of these unfortunate yet oftentimes reversible statistics.

Dr. Alan J. Bauman Reveals Bulletproof Founder Dave Asprey’s “Upgraded Hair” After His Bulletproof Radio Podcast on Biohacking Baldness

World-Renowned Hair Restoration Surgeon Dr Alan J Bauman Announces New Technologies to Detect Prevent Treat Hair Loss

The medical community also continues to see a correlation between COVID-19 and hair loss. The past 18 months have delivered unimaginable stressors and challenges. Excessive or prolonged psychological and physiological stress including fever-related illnesses can trigger heavy shedding (telogen effluvium) and accelerate hair loss.

Even those not physically infected with COVID can experience the detrimental effects of the Pandemic on their hair, scalp, and other organs. More than a quarter of patients recovering from COVID-19 have reported hair loss as one of the lingering problems from the illness.

Internationally recognized, ABHRS-Certified Hair Restoration Surgeon Dr Alan J. Bauman discusses the most efficient and effective protocols of hair loss prevention and highlights some of the newest technology in the field of hair restoration aimed at both preserving and restoring the hair.

According to Dr Bauman, who was recently named “Top Hair Restoration Surgeon of the Decade” by Aesthetic Everything®, “Early action is essential to improving the fate of the follicle. While most hair loss may be hereditary,” he states “with proper intervention, it’s also avoidable.” Because early detection and precise analysis are key to identifying the most accurate source of treatment, experts in hair restoration are celebrating the advancements in the science of hair loss detection.

ADVANCEMENTS IN DETECTION & TREATMENT

Trichotest® Genetic Hair Loss Testing performs genetic testing based on state-of-the-art DNA microarray technology to identify the exact hair loss treatments that will perform best for the patient based on DNA analysis. Trichotest® examines DNA from saliva together with details about the patients’ lifestyle and then analyzes a total of 48 genetic variations to understand specific characteristics of the metabolism which contribute to hair loss. Using proven scientifically validated global research, Trichotest® enables hair restoration experts to recommend the most successful treatment option.

HairMetrix® is the first Artificial Intelligence (AI) driven non-invasive hair measurement tool for consultations. Based on a machine-learning algorithm, the HairMetrix® system provides real-time analysis of hair density, hair calibre, and other metrics that contribute vital information to a Hair Restoration Physician and his patient by first establishing a baseline in more permanent areas of hair growth, and then comparing those measurements to weaker zones. HairMetrix® also allows for the precise tracking of hair growth results over time. Dr Bauman is one of the first physicians worldwide to use this new AI hair analysis system.

TREATING HAIR AT HOME

After a virtual or in-person consultation, at-home treatment programs include premium prescribed products such as specially formulated non-greasy highly-rated Minoxidil Formula 82M, to Formula 82F Topical Finasteride+Minoxidil and Formula 82D Topical Dutasteride+Minoxidil to the powerful FDA-cleared Bauman TURBO LaserCap Low-Level Laser Therapy device for hair regrowth, to bespoke Nutritional Supplements, and DHT-Control hair care products.

IN-OFFICE REGENERATIVE TREATMENTS

If at-home treatments don’t suffice, there are a plethora of in-office regenerative medicine treatments including PRP Platelet Rich Plasma, PDOgro™, Exosome Therapy, and other cell therapy interventions.

HAIR TRANSPLANTS

If an assessment confirms that hair follicles are dead and gone, a transplant is needed. Today’s state-of-the-art hair transplant technology includes the no-linear-scar, minimally-invasive FUE hair transplant surgery as well as the No-Shave Long-Hair Preview VIP|FUE™, a groundbreaking, minimally invasive hair transplant procedure. VIP|FUE™ delivers all the hair restoration benefits of traditional FUE without any shaving or trimming of hair.

Dr Bauman recently revealed Bulletproof Founder Dave Asprey’s “upgraded hair” at Asprey’s Virtual Biohacking Conference. Asprey, considered the “Father of Biohacking”, was at Bauman Medical last year for a 4,087 graft FUE hair transplant procedure, which also included PRP Platelet Rich Plasma with Extracellular Matrix, and followed up with at-home hair regrowth treatments using Dr Bauman’s FDA-cleared TURBO LaserCap. Asprey’s keen social media followers had already noticed “something different” about his hair and were amazed at his results. Dr Bauman will be a featured presenter discussing “Biohacking Baldness” at the upcoming in-person Upgrade 7th Annual Biohacking Conference in Orlando September 17-19.

To learn more about the newest advancements in hair restoration, please visit www.baumanmedical.com. For media interviews, please contact danna@canpublicity.com

About Alan J. Bauman, MD, ABHRS

Alan J. Bauman, MD, ABHRS is a full-time board-certified Hair Restoration Physician who has treated nearly 30,000 patients and performed over 10,000 hair transplant procedures since starting his medical hair loss practise, Bauman Medical, in 1997 in Boca Raton, FL.

Dr Bauman is one of approximately only 200 physicians worldwide to achieve certification from the esteemed American Board of Hair Restoration Surgery (ABHRS), become an accepted member of the International Alliance of Hair Restoration Surgeons (IAHRS), and also be recommended by the American Hair Loss Association. Dr Bauman has achieved the coveted Fellow status within the International Society of Hair Restoration Surgery (ISHRS), is a frequently invited faculty member at numerous international scientific meetings and live surgery workshops, and has published numerous articles and textbook chapters in the field of hair restoration and hair transplantation.

Dr Bauman has consistently been shortlisted for numerous Top Hair Transplant Surgeon recognitions and awards worldwide. He has been named “#1 Top Hair Restoration Surgeon” in North America by Aesthetic Everything for five years running and recently named by Forbes as one of “Ten CEOs Transforming Healthcare in America.” As a respected global expert in hair loss and hair restoration and a pioneer of many techniques, technologies and devices in the field, he has appeared in hundreds of feature stories and live interviews in the mass media and top health podcasts. In addition to lecturing and consulting worldwide, Dr Bauman sees patients personally and operates in his nearly 12,000 square foot “Hair Hospital” in downtown Boca Raton, FL.

August Is National Hair Loss Awareness Month

Source

Recent Posts

Global Anti-dandruff

Global Anti-dandruff

Global Anti-dandruff Agent Additive Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026

The Anti-dandruff Agent Additive market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, the impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Anti-dandruff Agent Additive size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Anti-dandruff Agent Additive market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation

Anti-dandruff Agent Additive market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Piroctone Olamine

Climbazole

Slaicylic Acid

Ketoconazole

Coal Tar

Selenium Sulfide

Other

Market segment by Application can be divided into

Personal Care

Pharmaceutical

The key market players for global Anti-dandruff Agent Additive market are listed below:

Clariant AG

Aurora Chemical

Spec Chem Group

Kumar Organic

Chemspec Chemicals

3C Pharmchem

Somu Group

Kolon Life Science

Regen Chemical

Symrise

Tinci Materials

Seqens SAS

Merck KGaA

Plater Group

Gaopeng Pharmaceutical

Kavya Pharma

Fengchen Technology

Xi’an Taicheng Chem

Market segment by Region, regional analysis covers

North America (the United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of the Middle East & Africa)

The content of the study subjects includes a total of 14 chapters:

Chapter 1, describe Anti-dandruff Agent Additive product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Anti-dandruff Agent Additive, with price, sales, revenue and global market share of Anti-dandruff Agent Additive from 2019 to 2021.

Chapter 3, the Anti-dandruff Agent Additive competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Anti-dandruff Agent Additive breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.

Chapters 5 and 6, segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Anti-dandruff Agent Additive market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.

Chapters 12, 13 and 14, describe Anti-dandruff Agent Additive sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Global Anti-dandruff Agent Additive Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026

Source

Recent Posts

Hair Loss Supplement Market

Hair Loss Supplement Market

Hair Loss Supplement Market Insights 2020, Global and Chinese Analysis and Forecast to 2024

Hair Loss Supplement Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Hair Loss Supplement industry with a focus on the Chinese market. The report provides key statistics on the market status of the Hair Loss Supplement manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry

.Overall, the report provides an in-depth insight into the 2014-2024 global and Chinese Hair Loss Supplement market covering all important parameters. The key points of the report:

1.The report provides a basic overview of the industry including its definition, applications and manufacturing technology.

2.The report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2014-2019 market shares for each company.

3.Through the statistical analysis, the report depicts the global and Chinese total market of the Hair Loss Supplement industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

4.The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

5.The report then estimates the 2019-2024 market development trends of the Hair Loss Supplement industry. Analysis of upstream raw materials, downstream demand and current market dynamics is also carried out.

6.The report makes some important proposals for a new project of the Hair Loss Supplement Industry before evaluating its feasibility. There are 3 key segments covered in this report: competitor segment, product type segment, end use/application segment.

For the competitor segment, the report includes global key players of Hair Loss Supplement as well as some small players. At least 4 companies are included:

* Nutrafol(US)
* Komplete Balance(US)
* ArtNaturals(US)
* Lia Wellness
The information for each competitor includes:

* Company Profile
* Main Business Information
* SWOT Analysis
* Sales, Revenue, Price and Gross Margin
* Market Share

For the product type segment, this report listed the main product type of the Hair Loss Supplement market global and in china.

* Tablets
* Capsules
* Others

For the end use/application segment, this report focuses on the status and outlook for key applications. End users are also listed.

* Individuals
* Clinics
* Others

Reasons to Purchase this Report:

* Estimates 2019-2024 Hair Loss Supplement market development trends with the recent trends and SWOT analysis
* Market dynamics scenario, along with growth opportunities of the market in the years to come
* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
* Regional and country-level analysis integrating the demand and supply forces that are influencing the growth of the market.
* Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
* 1-year analyst support, along with the data support in excel format. Any special requirements about this report, please let us know and we can provide a custom report.

Hair Loss Supplement Market Insights 2020, Global and Chinese Analysis and Forecast to 2024

Source

Recent Posts

Hair Loss Awareness Month

Hair Loss Awareness Month

Nutrafol Pledges to Open the Dialogue in Support of Hair Loss Awareness Month

Nutrafol, the pioneer of the hair wellness category, is committed to opening the dialogue around hair loss and thinning through trusted healthcare providers who empower and educate consumers on treatment options. Hair loss can have a strong impact on mental well-being, confidence and self-image among both men and women.

In support of Hair Loss Awareness Month, Nutrafol will donate a portion of total revenue for the month of August to the National Alopecia Areata Foundation. Nutrafol’s contribution will directly benefit the National Alopecia Areata Foundation (NAAF) Youth Mentor Program which helps young children with alopecia cope with the stress of hair loss in a meaningful way.

Hair loss is more common than many people realize. According to the American Hair Loss Association (americanhairloss.org), 40% of American hair loss sufferers are women and 85% of men will have significant hair thinning by the age of 50.  Health professionals are often a trusted resource for concerned men and women and play a significant role in empowering them with solutions such as Nutrafol hair growth supplements.

“At Nutrafol, we prioritize mental, emotional and physical health and well-being, equally. Hair loss and thinning are more than just a physical symptom, it’s an emotional journey for every single patient and we are committed to supporting and encouraging those suffering to take control of their hair health and regain their confidence,” said Dr. Sophia Kogan, co-founder and Chief Medical Advisor at Nutrafol.

Nutrafol’s clinically proven nutraceuticals improve hair growth by addressing the key triggers of poor hair health including stress, hormones, environment, immune response and gut microbiome. Nutrafol’s products are physician formulated with natural, clinically effective ingredients proven to improve hair growth without a prescription, and can easily be added to any daily routine. Nutrafol offers a men’s formulation and three options for women that are uniquely designed to address changing biological needs of women as they navigate life stages including postpartum and menopause.

For more information on Nutrafol, speak with your healthcare provider or visit www.nutrafol.com.

About Nutrafol

Nutrafol is the #1 Dermatologist recommended hair growth supplement brand* that pioneered the hair wellness category with its integrative approach to hair health, using a first-of-its-kind patented formulation of clinically effective, natural, medical-grade ingredients to support whole-body wellness from within. In multiple clinical studies, Nutrafol has been shown to improve hair growth in both men and women within 3-6  months by multi-targeting the root causes of thinning hair, including stress, hormones, environment and nutrition. Nutrafol’s team of doctors and researchers continue to seek out scientific advancements at the forefront of genetics, biotechnology, and anti-ageing medicine to remain on the cutting-edge of hair health innovation. Nutrafol has been adopted by more than 3,000 physicians, clinics and stylists across the U.S. for its trusted, reliable results, and has received numerous prestigious accolades.

*According to IQVIA ProVoice survey for 6 months ending March 31, 2021

About National Alopecia Areata Foundation

National Alopecia Areata Foundation (NAAF) deeply appreciates Nutrafol’s commitment to helping all of those with hair loss and helping the alopecia areata community by including NAAF as their social responsibility non-profit, during hair loss awareness month.

The National Alopecia Areata Foundation (NAAF) serves the community of people affected by an autoimmune skin disease called alopecia areata that results in hair loss and emotional pain. NAAF is a 501(c)(3) nonprofit organization founded in 1981 and headquartered in San Rafael, CA

Nutrafol Pledges to Open the Dialogue in Support of Hair Loss Awareness Month

Source

Minimally Invasive Hair Restoration Course

Minimally Invasive Hair Restoration Course

Anthony Bared MD, FACS to Teach Minimally Invasive Hair Restoration Course at Upcoming Miami Cosmetic Surgery Conference

One of Miami’s most accomplished facial plastic surgeons and hair restoration experts, Dr Anthony Bared, M.D., F.A.C.S., will be sharing his knowledge at the August MCS conference on the most effective hair restoration techniques and how cosmetics surgeons can begin to offer these procedures.

Dr Bared’s speciality course, Hair Restoration in Aesthetics, will take place on Saturday, August 28, 2021, between 8:15-9:45 AM in the America/Chicago rooms of the conference venue, the Miami Beach Convention Center.

The Miami Cosmetic Surgery (MCS) conference is considered a leading industry event where specialists, renowned researchers, educators, and practitioners convene to share and discuss cutting edge knowledge regarding advancements in cosmetic surgery. Dr Bared’s workshop is part of the overall conference which takes place from August 25-28th.

Dr Bared works alongside Dr Jeffrey Epstein at the Foundation for Hair Restoration for Plastic Surgery where he performs surgical and non-invasive procedures for the management of hair loss. At the MCS conference, Dr Bared will discuss the growing demand for hair loss treatments for men and women of all ages and the effective minimally invasive procedures cosmetic surgeons can incorporate into their practices to address and improve patient outcomes.

These include threads for hair restoration, various device-based and energy-based options, platelet-rich plasma (PRP), as well as topical and nutraceutical therapies. Course attendees will gain insights on effectively and efficiently incorporating these services into their aesthetic practices, resulting in new patients and high patient satisfaction.

“With the latest advancements in treatments for hair loss, there are many effective options that practitioners can quickly adapt as options for their current and prospective patients who are suffering from hair loss,” said Dr. Bared. “I regularly treat patients with these procedures, depending on the type and extent of hair loss that they are presenting with, and have seen positive results achieved with time and repeated treatments.”

He continued, “The extent to which these therapies affect patients suffering from hair loss should not be understated. They can make a marked improvement in patient confidence as well as add significant revenue streams to aesthetic practices.”

To learn more about Dr. Bared and the full suite of surgical and non-surgical procedures he performs, visit http://www.facialplasticsurgerymiami.com.

To learn more about the Miami Cosmetic Surgery conference and to register to attend, visit http://www.miamicosmeticsurgery.info/.

About Dr Anthony Bared

Dr Anthony Bared, M.D., F.A.C.S., is “Miami’s Facial Plastic Surgeon.” With training in Otolaryngology at the University of Miami followed by one of only forty spots for a highly competitive fellowship by the American Academy of Facial Plastic and Reconstructive Surgery at the University of Illinois – Chicago, Dr Bared is a celebrated double board-certified facial plastic surgeon.

He has authored numerous scientific articles and given lectures nationwide on various cosmetic specialities. As a talented and compassionate surgeon, Dr Bared provides rhinoplasty, injectables, hair loss management and more. Anthony Bared MD, FACS to Teach Minimally Invasive Hair Restoration Course at Upcoming Miami Cosmetic Surgery Conference

Source

Recent Posts

Trial of Ritlecitinib in Alopecia Areata

Trial of Ritlecitinib in Alopecia Areata

Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata

Pfizer Inc today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib in patients with alopecia areata, an autoimmune disease driven by an immune attack on the hair follicles that causes hair loss on the scalp and can also affect the face and body.1,2

Ritlecitinib 50 mg and 30 mg achieved the primary efficacy endpoint of the study, namely the proportion of patients with less than or equal to 20 per cent scalp hair loss after six months of treatment versus placebo.

European Medicines Agency approved treatments,” said Michael Corbo, PhD, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “We look forward to bringing this potential new treatment option to patients living with alopecia areata as soon as possible.”

The Phase 2b/3 ALLEGRO trial met the primary efficacy endpoint of improving scalp hair regrowth. All participants entered the study with at least 50 per cent scalp hair loss due to alopecia areata, as measured by the Severity of Alopecia Tool (SALT) score.

A statistically significantly greater proportion of patients who took ritlecitinib 30 mg or 50 mg once-daily, with or without a four-week initial treatment of 200 mg once-daily, had 20 per cent or less scalp hair loss (an absolute SALT score ≤20) after 24 weeks of treatment compared with placebo.

This was followed by a 24-week extension period, during which all participants initially randomized to receive ritlecitinib continued on the same regimen, while participants who received placebo during the initial 24 weeks advanced to one of two regimens: 200 mg for four weeks followed by 50 mg for 20 weeks, or 50 mg for 24 weeks. The study also included a 10 mg dosing arm, which was assessed for dose-ranging and was not tested for statistically significant efficacy compared to placebo.

The safety profile seen with ritlecitinib was consistent with previous studies. Overall, the percentage of patients with adverse events (AEs), serious AEs and discontinuing due to AEs was similar across all treatment groups.

The most common AEs seen in the study were nasopharyngitis, headache and upper respiratory tract infection. There were no major adverse cardiac events (MACE), deaths or opportunistic infections in the trial. Eight patients who were treated with ritlecitinib developed mild to moderate herpes zoster (shingles).

There was one case of pulmonary embolism in the ritlecitinib 50 mg group, which was reported to have occurred on Day 169. There were two malignancies (both breast cancers) reported in the ritlecitinib 50 mg group, which were reported to have occurred on Day 68 and Day 195. Both participants were discontinued from the study.

Full results from this study will be submitted for future scientific publication and presentation. These data, together with data that will become available from ALLEGRO-LT, will form the basis for planned future regulatory filings.

Ritlecitinib is the first in a new investigational class of covalent kinase inhibitors that have high selectivity for Janus kinase 3 (JAK3) and members of the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family. In laboratory studies, ritlecitinib has been shown to block the activity of signalling molecules and immune cells believed to contribute to loss of hair in people with alopecia areata.3

Ritlecitinib, which was granted Breakthrough Therapy designation from the U.S. FDA for the treatment of alopecia areata in September 2018, is also being evaluated for vitiligo, rheumatoid arthritis, Crohn’s disease and ulcerative colitis.

About the Phase 2b/3 ALLEGRO Trial

This randomized, placebo-controlled, double-blind study investigated ritlecitinib in patients 12 years of age and older with alopecia areata (n=718). Patients included in the study had 50 per cent or more hair loss of the scalp, including patients with alopecia totalis (complete scalp hair loss) and Alopecia Universalis (complete scalp, face and body hair loss), and were experiencing a current episode of alopecia areata that had lasted between six months and ten years. Patients were randomized to receive ritlecitinib 50 mg or 30 mg (with or without one month of initial treatment with once-daily ritlecitinib 200 mg), ritlecitinib 10 mg or placebo.

The primary endpoint was the proportion of patients with scalp hair regrowth in response to ritlecitinib treatment, based on an absolute SALT Score ≤20 at Week 24. SALT is a tool that measures the amount of scalp hair loss. The tool divides the scalp into standard regions, and each region contributes to the total SALT score, which ranges from 0 to 100. A SALT score of 0 corresponds to no scalp hair loss, while a SALT score of 100 corresponds to a total lack of hair on the scalp.4

More information about the Phase 2b/3 ALLEGRO trial can be found at https://www.clinicaltrials.gov under the identifier NCT03732807.

About Alopecia Areata

Alopecia areata is an autoimmune disease characterized by patchy hair loss, almost always involving the scalp, but sometimes also involving the face (eyebrows, eyelashes, beard), the whole scalp or the whole body.1,2 People suffering from alopecia areata experience symptoms when immune cells attack healthy hair follicles, causing the hair to fall out.1,2 The mean age of onset is between 25 and 35 years, but it can also impact older adults, children and adolescents, and is seen in both sexes and all ethnicities.1,2 Alopecia areata is associated with poor health-related quality of life for many patients, who may suffer from serious psychological consequences, including depression and anxiety.1

1 Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clinical, Cosmetic and Investigational Dermatology. 2015;8:397-403. doi:10.2147/CCID.S53985.

2 Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nature reviews Disease primers. 2017;3:17011. doi:10.1038/nrdp.2017.11.

3 King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, Zhu L, Cox LA, Craiglow B, Chen L, Banfield C, Page K, Zhang W, Vincent MS. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021 Mar 20:S0190-9622(21)00601-0. doi: 10.1016/j.jaad.2021.03.050.

4 Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines–part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51(3):440-447.

Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata

Source

Recent Posts

Hair Transplant Before and After Photos

Clinic for Female Hair Transplant

Silicon Valley Institute, Best Class Clinic for Female Hair Transplant, Announces New ‘Before and After’ Page for Women

Silicon Valley Hair Institute, a highly-rated Bay Area hair transplantation clinic is proud to announce a new page focused on women’s hair loss treatments. The newly released before-and-after photos of women’s hair restoration including hairline treatments are available to review.

“Women’s hair loss is not the same as men’s. We believe a page centred around their experiences may be helpful to the community,” explained Miguel Canales, MD. “Photos show our female patients before and after their hair loss treatments so the public can see the results for themselves.”

The public can review the new “before and after” page focused on female hairline restoration. Silicon Valley Institute, Best Class Clinic for Female Hair Transplant, Announces New ‘Before and After’ Page for Women Thinner, more brittle hair could be signs of female hair loss instead of a typical “receding” hairline found in men. A top clinic focused on female hair transplant support in the Bay Area can help residents review options.

Treatments for women can include the following: robotic hair transplant surgery, light therapy, and supplement protocols. The clinic serves both women and men prepared to address hair loss issues. Bay Area residents can review the clinic’s “before and after” page for men at https://siliconvalleyhairinstitute.com/before-after/.

Those looking for skincare issues are encouraged to visit the sister website at https://svaestheticderm.com/.

FEMALE HAIR TRANSPLANT CLINIC IN BAY AREA AIMS THE SPOTLIGHT ON WOMEN’S HAIR LOSS

Here is the background on this release. Baldness may be a common issue for men living in the San Francisco area. However, women struggling with thinning hair confront unique problems. Confusion over how to manage the problem and a loss of confidence could result from thinning hair in women.

For these reasons, Silicon Valley Hair Institute announces a new women-centred page of “before and after” examples of hair loss treatments, especially for hair line issues. Female hair loss can present as a widening part and all-over thinner hair. Treatments may include hair transplantation, nutritional protocols, and micro-pigmentation. A state-of-the-art clinic helps focus the spotlight on female hair transplant services in the Bay Area.

ABOUT THE SILICON VALLEY HAIR INSTITUTE

Silicon Valley Hair Institute under the leadership of top-rated California hair transplant surgeon Dr Miguel Canales – is one of the best robotic hair transplant clinics in the San Francisco Bay Area.

Dr Canales provides both the FUT (Follicular Unit Transplant and FUE hair transplant (Follicular Unit Extraction procedures.

Dr Canales is a top-rated hair transplant specialist for Bay Area residents. The Silicon Valley Hair Institute specializes in hair loss and hair restoration needs in San Francisco, San Jose, and the Silicon Valley Peninsula (Sunnyvale, Mountain View, Palo Alto, Los Altos, Menlo-Atherton, Redwood City, and beyond.). Dr Canales also specializes in aesthetic hair restoration for females seeking eyebrow transplantation or hairline advancements.

Silicon Valley Institute, Best Class Clinic for Female Hair Transplant, Announces New ‘Before and After’ Page for Women

Source

Recent Posts